# Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

> **NCT00211848** · PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 207 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Polyenylphosphatidylcholine (PPC)
- **DRUG:** Pegylated Interferon
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00211848
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2017-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211848, "Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00211848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*